Evans John M. 4
4 · Beam Therapeutics Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Beam Therapeutics CEO John M. Evans Exercises Options, Sells Shares
What Happened
- John M. Evans, CEO and Director of Beam Therapeutics (BEAM), exercised a total of 50,000 option-derived shares (18,663 @ $0.67; 6,337 @ $1.03; 25,000 @ $1.03) for a combined exercise cost of $44,781, and sold 50,000 common shares in open-market transactions for aggregate proceeds of approximately $1,745,037. The sales occurred on June 29–30, 2026 and were carried out under a Rule 10b5-1 trading plan.
Key Details
- Transaction dates: June 29, 2026 (exercises and some sales) and June 30, 2026 (exercise and sales).
- Exercises (acquisitions): 18,663 @ $0.67 ($12,504); 6,337 @ $1.03 ($6,527); 25,000 @ $1.03 ($25,750). Some derivative entries are shown as $0 in the filing to reflect conversion/derivative reporting.
- Sales (dispositions): 13,421 @ $35.13 (Wtd avg; range $34.55–$35.50); 11,579 @ $35.91 (Wtd avg; range $35.60–$36.18); 23,100 @ $34.26 (Wtd avg; range $33.80–$34.71); 1,900 @ $34.84 (Wtd avg; range $34.83–$34.85). Total shares sold = 50,000; total proceeds ≈ $1,745,037.
- Shares owned after transaction: not specified in the provided excerpt of the filing — see the full Form 4 for total post-transaction holdings.
- Notable footnotes: sales were made pursuant to a Rule 10b5-1 plan adopted May 16, 2025 (F1). Several sale prices are reported as weighted averages with provided price ranges (F2–F5). Earlier option grants and vesting details are noted in the filing (F6, F7).
- Filing timeliness: no late-filing indication in the provided data.
Context
- This was an option exercise immediately followed by market sales — commonly called a cashless or simultaneous exercise-and-sell under a 10b5-1 plan, which is a prearranged program allowing scheduled sales even for insiders.
- Such transactions are often routine liquidity events for insiders rather than an explicit signal about company outlook; purchases typically carry more weight as a bullish indicator. For full details (exact per-trade prices, total holdings before/after, and any tax withholdings), consult the full SEC Form 4 (Accession 0001193125-26-292526).
Insider Transaction Report
Form 4
Evans John M.
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-29$0.67/sh+18,663$12,504→ 1,065,868 total - Exercise/Conversion
Common Stock
[F1]2026-06-29$1.03/sh+6,337$6,527→ 1,072,205 total - Sale
Common Stock
[F1][F2]2026-06-29$35.13/sh−13,421$471,528→ 1,058,784 total - Sale
Common Stock
[F1][F3]2026-06-29$35.91/sh−11,579$415,824→ 1,047,205 total - Exercise/Conversion
Common Stock
[F1]2026-06-30$1.03/sh+25,000$25,750→ 1,072,205 total - Sale
Common Stock
[F1][F4]2026-06-30$34.26/sh−23,100$791,482→ 1,049,105 total - Sale
Common Stock
[F1][F5]2026-06-30$34.84/sh−1,900$66,203→ 1,047,205 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-06-29−18,663→ 9 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (18,663 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-06-29−6,337→ 230,804 totalExercise: $1.03Exp: 2028-07-13→ Common Stock (6,337 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-06-30−25,000→ 205,804 totalExercise: $1.03Exp: 2028-07-13→ Common Stock (25,000 underlying)
Holdings
- 103,000(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
- [F7]On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Signature
By: /s/ Christine Bellon, Attorney-in-fact|2026-07-01